Received Mar 23, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | 1 | UNK | — |
hypodermal sensitivity/rash; This non-serious case was reported by a consumer via call center representative and described the occurrence of sensitive skin in a female patient who received Herpes zoster (Shingrix) for prophylaxis. On an unknown date, the patient received the 1st dose of Shingrix. On an unknown date, an unknown time after receiving Shingrix, the patient experienced sensitive skin (Verbatim: hypodermal sensitivity/rash). The outcome of the sensitive skin was not reported. The reporter considered the sensitive skin to be related to Shingrix. The company considered the sensitive skin to be related to Shingrix. Linked case(s) involving the same patient: US2026036387 Additional Information: GSK Receipt Date: 17-MAR-2026 Patient had rash on her side after receiving the first dose of Shingrix, she was examined and was diagnosed with hypodermal sensitivity to the vaccine. Patient had the second dose and did not report any adverse event associated with the second dose. The batch number was not provided, and we are unable to contact the reporter.; Sender's Comments: US-GSK-US2026036387:same patient